Neomycin / polymyxin b / prednisolone ophthalmic Pregnancy and Breastfeeding Warnings

Brand names: Poly Pred

Neomycin / polymyxin b / prednisolone ophthalmic Pregnancy Warnings

Neomycin/polymyxin B/prednisolone ophthalmic has been assigned to pregnancy category C by the FDA. Animal studies have shown corticosteroids to be teratogenic in mice and rabbits following multiple dose topical ophthalmic application. There are no controlled data in human pregnancy. Neomycin/polymyxin B/prednisolone ophthalmic is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

Corticosteroids have been shown to produce fetal resorptions and cleft palate in mice. In addition, they have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, and palate in rabbits.

See references

Neomycin / polymyxin b / prednisolone ophthalmic Breastfeeding Warnings

There are no data on the excretion of neomycin/polymyxin B/prednisolone ophthalmic into human milk. Topically applied steroids have been reported to be absorbed systemically. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue the drug or to discontinue nursing, taking into account the importance of the drug to the mother. Prednisolone is considered compatible with breast-feeding by the American Academy of Pediatrics.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer